Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.06 ?g per 10⁶ cells in 100 ?l volume. For immunohistochemistry on frozen tissue sections, a concentration range of 5.0 - 10 ?g/ml is suggested. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 ?g/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 488 has a maximum emission of 519 nm when it is excited at 488 nm.

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^2,3,11 and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)

1. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
2. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
3. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
4. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
5. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
6. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
7. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
8. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
9. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
10. White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed
11. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
12. Wallace-Povirk A, et al. 2022. Sci Rep. 12:11346. PubMed
13. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
14. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
15. Song W, et al. 2022. Immunity. 55:290. PubMed

Majority of thymocytes, T cell subset

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.